BCL-2 inhibitors such as venetoclax have demonstrated therapeutic synergy with ruxolitinib by blocking IL-7/ IL-7Rα signaling in T-ALL(68–72). This evidence concerns the gene IL7R and acute lymphoblastic leukemia.